One in eleven 18-year-olds in the Avon Longitudinal Study of Parents and Children (ALSPAC) reports psychotic experiences like hallucinations or delusions, and a new round of brain scans will track whether those symptoms persist as the same individuals turn 26. The problem is that no one knows how the brain’s continuing development through young adulthood drives these experiences—or why some people’s symptoms fade while others go on to develop schizophrenia, depression, or long-term unemployment. Earlier scans at age 20 found subtle changes in brain volume and connectivity in those with psychotic experiences, but a single snapshot cannot reveal whether those changes are temporary, progressive, or linked to genetic risk or inflammation. By re-scanning roughly 450 participants with structural, diffusion, and functional MRI, the team will map trajectories of brain change and test whether persistent symptoms follow abnormal developmental pathways. They will also link those brain measures to genetic risk scores and childhood blood markers of inflammation. If successful, this work could identify early biological markers that distinguish transient adolescent symptoms from those that foreshadow serious mental illness—guiding when and how to intervene before a first psychotic episode.
View original technical description
The Avon Longitudinal Study of Parents and Children (ALSPAC) has shown that over 9% of 18 year olds have psychotic experiences (PEs) such as hallucinations and delusions, verified by trained psychologists and using strict criteria. When persistent, PEs increase the likelihood of a person developing psychotic disorders such as schizophrenia, other psychiatric conditions (eg depression) and poor psychosocial outcomes such as unemployment. PEs can sometimes recede as people pass from adolescence to adulthood but we don't know how changes in the brain, which continues to develop and mature through these years, underlie and affect PEs. Thanks to grants from the MRC, we have recently shown, using magnetic resonance imaging (MRI) brain scans, that at age 20+, individuals from ALSPAC with PEs have small changes in regional brain volumes, and global and local connectivity which cannot be ascribed to the consequences of having a psychiatric diagnosis or treatment with medication. We have also shown that individuals from ALSPAC who may be at a slightly increased risk of psychosis due to their genetic makeup (using a 'risk score' made out of the contribution of the many genes which when added together, are associated with a small but significantly increased risk of schizophrenia) also have subtle changes in brain thickness and volume. Our objective is to re-scan these same individuals, numbering about 450 in total, at age 26 using the full range of MRI scanning techniques. This will enable us to test the hypothesis that persistent PEs are underpinned by anomalous pathways or trajectories of brain development and abnormalities in function, as compared with those without PEs and against their original baseline scans. Additional objectives are to plot changes in cognition (using IQ tests) that we expect might show some decline in those with persistent PEs. We will make use of the latest genetic risk score for schizophrenia from genome-wide association studies available in ALSPAC to examine the potential of our brain measures to be used as intermediate links between genes and clinical outcomes. Finally we will see if blood markers of inflammation which can act on the brain, measured in the same individuals when they were children and again when adults, might explain the brain changes we see on MRI. We will use a powerful MRI brain scanner located in Cardiff to obtain detailed structural images and measures of grey and white matter volumes and a particular variant of scanning called diffusion MRI that quantifies the microscopic properties of white matter tracts - nature's wires - that connect together groups of brain cells. Functional MRI, which picks up those parts of the brain that are more active during a task, will be carried out while participants are trying to remember a sequence of letters and also while they are at rest (although their brains will still be working). This will help us to determine the degree of physiological compromise/compensation evident in the brain in those with PEs and structural changes. This will also help us look at how the different specialised parts of the brain are working together as a coherent unit. This project will enable us to map the change in brain development in young people with and without potentially important psychotic experiences (PEs) taken from ALSPAC, one of the most well-studied epidemiological samples available to medical science. Because there is such a wealth of information available, it means that when we analyse the brain scans we can take into account lots of other factors that might otherwise obscure or falsely exaggerate the effects of PEs such as cannabis and alcohol misuse. The project as a whole has the potential to advance our understanding of the biological basis of psychotic and related disorders and to help guide the development of primary prevention and early intervention strategies in mental health care.
Andy Boyd (Co-Investigator)Anthony David (Principal Investigator)Avi Reichenberg (Co-Investigator)Bianca De Stavola (Co-Investigator)Derek Jones (Co-Investigator)Edward Bullmore (Co-Investigator)Glyn Lewis (Co-Investigator)Matthew Kempton (Co-Investigator)Stanley Zammit (Co-Investigator)
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know